(Q38004853)

26 August 2017

Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers (English)

1 reference

26 August 2017

1 reference

Rita Nahta

1

1 reference

26 August 2017

Ruth M O'Regan

series ordinal

2

1 reference

26 August 2017

language of work or name

English

0 references

publication date

20 April 2012

1 reference

Breast Cancer Research and Treatment

26 August 2017

1 reference

26 August 2017

135

1 reference

26 August 2017

1

1 reference

26 August 2017

39-48

1 reference

https://scigraph.springernature.com/pub.10.1007/s10549-012-2067-8

26 August 2017

0 references

cites work

Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

Increased HER2/neu expression in recurrent hormone receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

Dual HER2-targeted approaches in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

Gene-expression signatures in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

Adjuvant trastuzumab in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

Molecular and cellular determinants of estrogen receptor alpha expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

Regulation of estrogen receptor-alpha gene expression by epidermal growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

HER2 therapy: molecular mechanisms of trastuzumab resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

TGFalpha expression impairs Trastuzumab-induced HER2 downregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

A cytoplasmic substrate of mitogen-activated protein kinase is responsible for estrogen receptor-alpha down-regulation in breast cancer cells: the role of nuclear factor-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2067-8

10.1007/S10549-012-2067-8

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

26 August 2017

0 references

1 reference